Ryvyl Inc Announces 1-for-35 Reverse Split, Shares Plunge 14.4%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy AGL?
Source: Benzinga
- Reverse Split Announcement: Ryvyl Inc's announcement of a 1-for-35 reverse stock split to regain Nasdaq's $1 minimum bid compliance led to a pre-market plunge of 14.4% in share price to $0.13, indicating a significant loss of investor confidence and potential liquidity issues.
- Market Reaction: Following the reverse split news, Ryvyl's shares fell sharply, reflecting market concerns about the company's future prospects, which could hinder its ability to raise capital and maintain competitive positioning.
- Other Stock Movements: Shares of Mink Therapeutics and SMX dropped 13.4% and 8.2% respectively, illustrating a broader market sentiment decline that may negatively impact investor confidence across related sectors.
- Industry Impact: Despite NeoGenomics' 7.1% decline in share price, the appointment of industry veteran John P. Kenny to its Board may provide a strategic turning point for the company, potentially enhancing its competitive edge in the diagnostics and lab services market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise
10 Analyst Rating
1 Buy
7 Hold
2 Sell
Hold
Current: 0.363
Low
0.50
Averages
0.98
High
1.50
Current: 0.363
Low
0.50
Averages
0.98
High
1.50
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health (NYSE: AGL) securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors can participate in the class action without any upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors until compensation is secured.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false or misleading statements during the class period, resulting in investor losses when the true situation was revealed, indicating significant misjudgments in the company's financial outlook that could affect future market trust.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases, which investors should consider when selecting legal counsel.
See More
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against agilon health related to securities transactions between February 26, 2025, and August 4, 2025, urging investors to contact them before the March 2, 2026, deadline to seek lead plaintiff status.
- Earnings Warning Impact: agilon health's August 4, 2025, earnings report revealed a decision to suspend its previously issued financial guidance for 2025 due to worsening industry headwinds, resulting in a 51.5% stock price drop the following day, indicating severe market concerns about the company's outlook.
- False Statement Allegations: The lawsuit alleges that agilon health and its executives recklessly issued guidance they knew was unattainable and failed to disclose significant industry challenges, leading to investor losses and highlighting serious deficiencies in corporate governance and transparency.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information, including former employees and shareholders, to come forward to support the investigation, emphasizing the importance of protecting investor rights and providing legal support for affected investors.
See More
- SLM Corporation Lawsuit: SLM Corporation (NASDAQ:SLM) is facing allegations for failing to disclose a significant rise in early-stage delinquencies during the class period from July 25 to August 14, 2025, misleading investors about the company's business stability, with a lead plaintiff deadline of February 17, 2026.
- Klarna Group Allegations: Klarna Group plc (NYSE:KLAR) is accused of materially understating the risks associated with its loss reserves during its September 2025 IPO, leading to misleading positive statements about its business prospects, with a lead plaintiff deadline of February 20, 2026.
- agilon Health Issues: agilon health, inc. (NYSE:AGL) is under scrutiny for issuing unrealistic guidance for 2025 amid known industry headwinds, misleading investors about the financial impact of its strategic actions, with a lead plaintiff deadline of March 2, 2026.
- Fermi Inc. Lawsuit: Fermi Inc. (NASDAQ:FRMI) faces allegations of overstating tenant demand for its Project Matador and failing to disclose reliance on a single tenant's funding, misleading investors about its business outlook, with a lead plaintiff deadline of March 6, 2026.
See More
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health, seeking damages for investors who purchased securities between February 26, 2025, and August 4, 2025, highlighting serious concerns over the company's financial transparency.
- False Statement Allegations: The complaint alleges that the defendants made false and misleading statements throughout the class period, particularly regarding their 2026 performance guidance, indicating a failure to disclose financial realities amidst industry challenges, which could lead to significant investor losses.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal proceedings in protecting investor rights.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, demonstrating its expertise in upholding market integrity.
See More
- Leadership Transition: Agilon Health announced the resignation of CEO Steven Sell and withdrew its full-year 2025 earnings guidance in its Q2 2025 earnings report, indicating instability in management that could undermine investor confidence.
- Stock Price Plunge: Following the release of this news, Agilon's shares fell over 27% in after-hours trading, reflecting market concerns about the company's future performance and potentially leading to significant losses for investors.
- Legal Investigation Initiated: DJS Law Group is investigating whether Agilon made misleading statements or failed to disclose information pertinent to investors, which could expose the company to legal liabilities and further exacerbate investor anxiety.
- Investor Rights Protection: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, indicating its commitment to providing legal support for affected investors, potentially leading to compensation opportunities.
See More
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Agilon Health, encouraging those who purchased AGL shares between February 26, 2025, and August 4, 2025, to contact the firm regarding potential lead plaintiff appointment for possible recovery.
- Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose significant industry headwinds, leading to an overly optimistic financial guidance for 2025 that misled shareholders.
- Participation Requirements: Once registered, shareholders will be enrolled in a portfolio monitoring software that provides status updates throughout the case lifecycle, with the deadline to seek lead plaintiff status set for March 2, 2026, and participation incurs no cost or obligation.
- Law Firm Credentials: The Gross Law Firm is a nationally recognized class action law firm committed to protecting the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the need for companies to adhere to responsible business practices.
See More






